The book highlights important new research using current state-of-the-art approaches by prominent researchers in the field of depression. A broad range of topics is covered, beginning with a description of the phenotypic features of clinical depression, followed by chapters on the cellular and molecular basis, functional neuroimaging correlates and information-processing accounts. Finally, existing and novel treatment approaches are covered. In this way the volume brings together the key disciplines involved in the neurobiological understanding of depression to provide an update of the field and outlook to the future. Together, the volume chapters provide focused and critical reviews that span a broad range of topics suitable for both students and established investigators interested in the present state of depression research.

Major depressive disorders have recently been associated with impairments in signaling pathways that regulate neuroplasticity and cell survival. Agents designed to directly target molecules in these pathways hold promise as new therapeutics for depression. With the collaboration of the most prestigious international specialists in biochemistry, mol

The Neuroscience of Depression: Features, Diagnosis and Treatment, is a comprehensive reference to the diagnosis and treatment of depression. This book provides readers with the mechanisms of depression reflecting on the interplay between depression and the biological and psychosocial processes. A detailed introduction to various episodes of depression, from PTSD to post-partum depression is provided, followed by a thorough discussion on biomarkers in depression and how to diagnose depression including the Hamilton Depression Rating scale. This book also includes three full sections on treatment options for depression, including pharmacological, behavioral and other novel regimes. The Neuroscience of Depression: Features, Diagnosis and Treatment is the only resource for researchers and practitioners studying, diagnosis and treating of depression. - Covers a pharmacological and behavioral treatment options - Features sections on diagnosis and biomarkers of depression - Discusses depression in children, teens and adults - Contains information on comorbidity of physical and mental conditions - Includes more than 250 illustrations and tables

Depression is one of the most common mental-health disorders, caused by a variety of genetic, biological, environmental, and psychological factors combined. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission; however, only approximately one third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness, and certain symptomatic clusters may be promising targets for novel therapeutics, such as drug and psychological treatments for the management of the cognitive impairments that can encompass several domains and contribute to psychosocial function, and that can persist for many patients even in periods of symptomatic remission. Neurobiology of Depression synthesizes the basic neurobiology of major depressive disorder with discussion of the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing researchers' perspectives and may revolutionize research into depression. The basic foundational understanding of the neurobiology underlying the disorder, as well as the comprehensive summary of the most recent advances in research, combine to aid advanced students and researchers in their understanding of MDD and change the landscape of the management of depression with the development of novel and fast-acting pharmaceutical and neuromodulatory approaches. Aids readers in understanding major depressive disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations Covers range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments to antidepressants to novel therapeutics Synthesizes discussion of cellular and molecular mechanisms underlying symptoms with clinical aspects of depression for a thorough understanding of the disorder

Behavioral Neuroscientists study the behavior of animals and humans and the neurobiological and physiological processes that control it. Behavior is the ultimate function of the nervous system, and the study of it is very multidisciplinary. Disorders of behavior in humans touch millions of people’s lives significantly, and it is of paramount importance to understand pathological conditions such as addictions, anxiety, depression, schizophrenia, autism among others, in order to be able to develop new treatment possibilities. Encyclopedia of Behavioral Neuroscience is the first and only multi-volume reference to comprehensively cover the foundation knowledge in the field. This three volume work is edited by world renowned behavioral neuroscientists George F. Koob, The Scripps Research Institute, Michel Le Moal, Université Bordeaux, and Richard F. Thompson, University of Southern California and written by a premier selection of the leading scientists in their respective fields. Each section is edited by a specialist in the relevant area. The important research in all areas of Behavioral Neuroscience is covered in a total of 210 chapters on topics ranging from neuroethology and learning and memory, to behavioral disorders and psychiatric diseases. The only comprehensive Encyclopedia of Behavioral Neuroscience on the market Addresses all recent advances in the field Written and edited by an international group of leading researchers, truly representative of the behavioral neuroscience community Includes many entries on the advances in our knowledge of the neurobiological basis of complex behavioral, psychiatric, and neurological disorders Richly illustrated in full color Extensively cross referenced to serve as the go-to reference for students and researchers alike The online version features full searching, navigation, and linking functionality An essential resource for libraries serving neuroscientists, psychologists, neuropharmacologists, and psychiatrists

With recent studies using genetic, epigenetic, and other molecular and neurochemical approaches, a new era has begun in understanding pathophysiology of suicide. Emerging evidence suggests that neurobiological factors are not only critical in providing potential risk factors but also provide a promising approach to develop more effective treatment and prevention strategies. The Neurobiological Basis of Suicide discusses the most recent findings in suicide neurobiology. Psychological, psychosocial, and cultural factors are important in determining the risk factors for suicide; however, they offer weak prediction and can be of little clinical use. Interestingly, cognitive characteristics are different among depressed suicidal and depressed nonsuicidal subjects, and could be involved in the development of suicidal behavior. The characterization of the neurobiological basis of suicide is in delineating the risk factors associated with suicide. The Neurobiological Basis of Suicide focuses on how and why these neurobiological factors are crucial in the pathogenic mechanisms of suicidal behavior and how these findings can be transformed into potential therapeutic applications.

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. - Provides efficacy research on ketamine as a treatment for depression - Identifies best practices for clinical use, both long-term and acute - Discusses the molecular mechanisms and neurobiology of action

Depression is a widespread condition affecting approximately 7.5 million parents in the U.S. each year and may be putting at least 15 million children at risk for adverse health outcomes. Based on evidentiary studies, major depression in either parent can interfere with parenting quality and increase the risk of children developing mental, behavioral and social problems. Depression in Parents, Parenting, and Children highlights disparities in the prevalence, identification, treatment, and prevention of parental depression among different sociodemographic populations. It also outlines strategies for effective intervention and identifies the need for a more interdisciplinary approach that takes biological, psychological, behavioral, interpersonal, and social contexts into consideration. A major challenge to the effective management of parental depression is developing a treatment and prevention strategy that can be introduced within a two-generation framework, conducive for parents and their children. Thus far, both the federal and state response to the problem has been fragmented, poorly funded, and lacking proper oversight. This study examines options for widespread implementation of best practices as well as strategies that can be effective in diverse service settings for diverse populations of children and their families. The delivery of adequate screening and successful detection and treatment of a depressive illness and prevention of its effects on parenting and the health of children is a formidable challenge to modern health care systems. This study offers seven solid recommendations designed to increase awareness about and remove barriers to care for both the depressed adult and prevention of effects in the child. The report will be of particular interest to federal health officers, mental and behavioral health providers in diverse parts of health care delivery systems, health policy staff, state legislators, and the general public.

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

The most comprehensive volume of its kind, The Oxford Handbook of Mood Disorders provides detailed coverage of the characterization, understanding, and treatment of mood disorders. Chapters are written by the world's leading experts in their respective areas. The Handbook provides coverage of unipolar depression, bipolar disorder, and variants of these disorders. Current approaches to classifying the mood disorders are reviewed and contemporary controversies are placed in historical context. Chapter authors offer a variety of approaches to understanding the heterogeneity of the experiences of those who meet criteria for mood disorders, both within and across cultures. The role of genetic and environmental risk factors as well as premorbid personality and cognitive processes in the development of mood pathology are detailed. Interpersonal, neurobiological, and psychological factors also receive detailed consideration. The volume reviews mood disorders in special populations (e.g., postpartum and seasonal mood disorders) as well as common comorbidities (e.g., anxiety, substance use disorders). Somatic and psychosocial treatment approaches receive in-depth coverage with chapters that describe and review empirical evidence regarding each of the most influential treatment approaches. The depth and breadth offered by this Handbook make it an invaluable resource for clinicians and researchers, as well as scholars and students.